Advertisement

Topics

[Comment] Early-stage breast cancer: falling risks and emerging options

21:29 EDT 2 Aug 2017 | The Lancet

Great improvements in the therapeutic ratio of cancer treatment can result from innovative approaches that maintain tumour control benefits while lowering treatment-associated morbidity. The IMPORT LOW trial by Charlotte Coles and colleagues1 in The Lancet is a high-quality randomised trial of treatment de-escalation in the multidisciplinary management of breast cancer.

Original Article: [Comment] Early-stage breast cancer: falling risks and emerging options

NEXT ARTICLE

More From BioPortfolio on "[Comment] Early-stage breast cancer: falling risks and emerging options"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...